Lubiprostone Can Be Started During Amitriptyline Taper
You can safely start lubiprostone (Amitiza) while the patient is tapering amitriptyline—there is no need to wait for complete discontinuation. There are no documented drug-drug interactions between these medications, and no contraindications exist for concurrent use.
Pharmacological Rationale
Lubiprostone has negligible systemic absorption 1. It acts locally on type 2 chloride channels in the intestinal epithelium without significant systemic effects 1. This local mechanism of action means there is no pharmacokinetic or pharmacodynamic interaction with systemically absorbed medications like amitriptyline.
The FDA drug label for amitriptyline 2 does not list lubiprostone as a contraindicated or interacting medication. The only significant drug interaction warning for amitriptyline involves:
- MAO inhibitors (14-day washout required)
- Cisapride (due to QT prolongation risk)
Similarly, the FDA label for lubiprostone 3 contains no warnings about tricyclic antidepressants or any need to avoid concurrent use with other medications beyond those causing mechanical GI obstruction.
Clinical Considerations
Overlapping Side Effects to Monitor
While concurrent use is safe, be aware that both medications can cause:
- Constipation from amitriptyline (anticholinergic effect) versus diarrhea from lubiprostone (5.30 times higher risk than placebo) 1
- Nausea: Lubiprostone causes nausea in up to 35% of patients 1, though this is typically mild to moderate and leads to discontinuation in only 5% 1
These opposing GI effects may actually balance each other during the taper period, though this is not evidence-based.
Practical Implementation
Start lubiprostone at the FDA-approved dose:
- 24 mcg twice daily with food and water for chronic idiopathic constipation 1, 3
- Taking with food significantly reduces nausea risk 1
- Effects typically manifest within 2 days in responders 1
Continue the amitriptyline taper as planned without modification. The 2023 AGA-ACG guidelines 1 make no mention of needing to discontinue other medications before starting lubiprostone, and implementation considerations specifically note it "can be used as a replacement or as an adjunct" to other agents 1.
Bottom Line
There is no pharmacological, regulatory, or guideline-based reason to delay lubiprostone initiation during amitriptyline taper. The negligible systemic absorption of lubiprostone eliminates interaction concerns, and no contraindications exist for concurrent use.